Kuda Therapeutics LLC is pre-clinical drug development company strcurured around novel therapies targeting the pathways of iron and oxygen sensing in cancer. With theo bjective of accelerating the translation of innovative science into transformative precision medicine, the firm's principals have dentified small molecule inhibitors that block the synthesis of Hypoxia-Inducible Factor (HIF)-2?, a well-validated target in kidney cancer. By blocking HIF-2? production, Kuda Therapeutic's molecules effectively block both the transcriptional and non-transcriptional targets of HIF-2?. These molecules act by affecting the ability of tumor cells to sense and utilize iron, thus mediating the dual and profound benefit of targeting two central drivers of CCRCC HIF-2? and iron accumulation. The firm's compounds effectively kill cancer cells in vitro and in vivo by promoting ferroptosis (iron-dependent cell death). The firm has indicated that their lead compounds have been demonstated significantlyto inhibit tumor growth in mouse models of kidney cancer with no apparent toxicities at the therapeutic dose.
